drugset
drugset / Trial / NCT04728646

Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes

NCT04728646 ↗

Phase 4 Withdrawn Massachusetts Eye and Ear Infirmary Ocular Therapeutix, Inc. · collab
RandomizedCrossoverSingle-blindTreatment

Summary

To evaluate the safety and efficacy of Dextenza intracanalicular insert in patients with ocular graft-versus-host disease (GVHD).

Timeline

Start
2021-09
Primary completion
2021-12-13
Completion
2021-12-13

Outcome

Outcome not reported

Stopped (Enrollment): “Due to difficulty enrolling subjects whom had not meet the inclusion criteria”

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 0.4 mg Other

Indications

chronic graft versus host disease